Previous close | 5.59 |
Open | 5.59 |
Bid | 3.60 |
Ask | 8.00 |
Strike | 85.00 |
Expiry date | 2024-08-16 |
Day's range | 5.59 - 5.59 |
Contract range | N/A |
Volume | |
Open interest | 5 |
JUPITER, Fla., May 23, 2024--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Todd Davis (Chief Executive Officer) and Tavo Espinoza (Chief Financial Officer) will participate in the following upcoming investor conferences:
AstraZeneca (AZN) targets $80 billion in total revenues by 2030. It expects to launch 20 new medicines.
Dyne (DYN) gains 28% after reporting positive new data from two separate ongoing mid to late-stage studies evaluating DYNE-101 and DYNE-251 for different muscle disease indications.